{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T01:10:30Z","timestamp":1780362630942,"version":"3.54.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.clml.2020.01.018","type":"journal-article","created":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T03:48:34Z","timestamp":1580788114000},"page":"422-430","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["18F-FDG PET or PET\/CT in Mantle Cell Lymphoma"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0810-6494","authenticated-orcid":false,"given":"Domenico","family":"Albano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Treglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gazzilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9410-7671","authenticated-orcid":false,"given":"Elisabetta","family":"Cerudelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Giubbini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bertagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2020.01.018_bib1","series-title":"World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"key":"10.1016\/j.clml.2020.01.018_bib2","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1182\/blood-2018-03-791392","article-title":"Update on mantle cell lymphoma","volume":"132","author":"Maddocks","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.01.018_bib3","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A\u00a0new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.01.018_bib4","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.01.018_bib5","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.01.018_bib6","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3389\/fmed.2019.00070","article-title":"Interest of FDG-PET in the managment of mantle cell lymphoma","volume":"9","author":"Bailly","year":"2019","journal-title":"Front Med"},{"key":"10.1016\/j.clml.2020.01.018_bib7","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1080\/10428190802311433","article-title":"What is the role of 18F-fluorodeoxyglucose positron emission tomography in mantle cell lymphoma?","volume":"49","author":"Gill","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.01.018_bib8","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1080\/10428190802382780","article-title":"The mysteries of mantle cell lymphoma-do PET scans provide a clue?","volume":"49","author":"Link","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.01.018_bib9","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3816\/CLM.2008.n.019","article-title":"[18F]Fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma","volume":"8","author":"Gill","year":"2008","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2020.01.018_bib10","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1080\/10428190802216707","article-title":"Positron emission tomography in mantle cell lymphoma","volume":"49","author":"Brepoels","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.01.018_bib11","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1097\/MNM.0b013e32832e0c13","article-title":"FDG positron emission tomography\/computed tomography scan may identify mantle cell lymphoma patients with unusually favorable outcome","volume":"30","author":"Karam","year":"2009","journal-title":"Nucl Med Comm"},{"key":"10.1016\/j.clml.2020.01.018_bib12","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1007\/s00259-010-1469-2","article-title":"Prognostic impact of 18F-fluorodeoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from GOELAMS group","volume":"37","author":"Bodet-Milin","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clml.2020.01.018_bib13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2967\/jnumed.109.067892","article-title":"(18)F-FDG avidity in lymphoma readdressed: a study of 766 patients","volume":"51","author":"Weiler-Sagie","year":"2010","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.clml.2020.01.018_bib14","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1002\/cncr.26731","article-title":"Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD","volume":"118","author":"Mato","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2020.01.018_bib15","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/ajh.22126","article-title":"Utility of positron emission tomography scans in mantle cell lymphoma","volume":"86","author":"Hosein","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2020.01.018_bib16","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1349-7006.2010.01802.x","article-title":"Relevance of monitoring metabolic reduction in patients with relapsed or refractory follicular and mantle cell lymphoma receiving bendamustine: a multicenter study","volume":"102","author":"Tateishi","year":"2011","journal-title":"Cancer Sci"},{"key":"10.1016\/j.clml.2020.01.018_bib17","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.clml.2011.03.013","article-title":"Fluorodeoxyglucose-positron-emission tomography findings in mantle cell lymphoma","volume":"11","author":"Alavi","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2020.01.018_bib18","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/bmt.2013.46","article-title":"Association of pre-transplantation positron emission tomography\/computed tomography and outcome in mantle cell lymphoma","volume":"48","author":"Cohen","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2020.01.018_bib19","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.3109\/10428194.2014.882506","article-title":"Is there a role for therapy response assessment with 2-[fluorine-18] fluoro-2-deoxy-D-glucose-positron emission tomography\/computed tomography in mantle cell lymphoma?","volume":"55","author":"Kedmi","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.01.018_bib20","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.clml.2013.10.007","article-title":"Hematopoietic cell transplantation for mantle cell lymphoma: predictive value of pretransplant positron emission tomography\/computed tomography and bone marrow evaluations for outcomes","volume":"14","author":"Magnusson","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2020.01.018_bib21","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1007\/s00277-015-2478-9","article-title":"Phase II study of bendamustine combined with rituximab in relapsed\/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings","volume":"94","author":"Czuczman","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2020.01.018_bib22","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/imj.13179","article-title":"PET-CT confirmed complete remission and MRD negativity in mantle cell lymphoma patients treated with R-hyper-CVAD results in excellent outcome in the absence of autologous stem cell transplantation: a single centre case for a transplant-free approach","volume":"46","author":"Htet","year":"2016","journal-title":"Intern Med J"},{"key":"10.1016\/j.clml.2020.01.018_bib23","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1080\/10428194.2017.1361032","article-title":"Surveillance imaging in mantle cell lymphoma in first remission lacks clinical utility","volume":"59","author":"Guidot","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.01.018_bib24","doi-asserted-by":"crossref","first-page":"62","DOI":"10.2967\/jnumed.116.173542","article-title":"18F-FDG PET for measurement of response and prediction of outcome to relapsed or refractory mantle cell lymphoma therapy with bendamustine\u2013rituximab","volume":"58","author":"Lamonica","year":"2017","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.clml.2020.01.018_bib25","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/j.bbmt.2017.07.006","article-title":"Long-term results of high-dose therapy and autologous stem cell transplantation for mantle cell lymphoma: effectiveness of maintenance rituximab","volume":"23","author":"Mei","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2020.01.018_bib26","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/hon.2483","article-title":"Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma","volume":"36","author":"Klener","year":"2018","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2020.01.018_bib27","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.clml.2018.06.024","article-title":"Positron emission tomography-based analysis can accurately predict bone marrow involvement with Mantle Cell Lymphoma","volume":"18","author":"Morgan","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2020.01.018_bib28","doi-asserted-by":"crossref","first-page":"e457","DOI":"10.1016\/j.clml.2019.04.016","article-title":"Diagnostic and clinical impact of staging 18F-FDG PET\/CT in mantle-cell lymphoma: a two-center experience","volume":"19","author":"Albano","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2020.01.018_bib29","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.3324\/haematol.2019.223016","article-title":"Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project","volume":"105","author":"Bailly","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2020.01.018_bib30","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s12149-019-01354-9","article-title":"Prognostic role of baseline 18F-FDG PET\/CT metabolic parameters in mantle cell lymphoma","volume":"33","author":"Albano","year":"2019","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.clml.2020.01.018_bib31","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1007\/s00259-019-04420-6","article-title":"Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma","volume":"46","author":"Mayerhoefer","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clml.2020.01.018_bib32","article-title":"Prognostic impact of interim positron emission tomography in mantle cell lymphoma patients treated with frontline R-CHOP","author":"Jeon","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.01.018_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11121831","article-title":"The role of 18F-FDG PET\/CT in staging and prognostication of mantle cell lymphoma: an Italian multicentric study","volume":"11","author":"Albano","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2020.01.018_bib34","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1136\/jcp.43.8.630","article-title":"Value of bilateral bone marrow biopsy specimens in non-Hodgkin\u2019s lymphoma","volume":"43","author":"Juneja","year":"1990","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.clml.2020.01.018_bib35","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/annonc\/mdt533","article-title":"Systematic review and meta-analysis on the diagnostic performance of FDG-PET\/CT in detecting bone marrow involvement in newly diagnosed Hodgkin lymphoma: is bone marrow biopsy still necessary?","volume":"25","author":"Adams","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2020.01.018_bib36","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00259-013-2623-4","article-title":"FDG PET\/CT for the detection of bone marrow involvement in diffuse large B cell lymphoma: systematic review and meta-analysis","volume":"41","author":"Adams","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clml.2020.01.018_bib37","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00259-007-0563-6","article-title":"High and typical 18F-FDG bowel uptake in patients treated with metformin","volume":"35","author":"Gontier","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clml.2020.01.018_bib38","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/RLU.0b013e318217399e","article-title":"Increased F-18 FDG intestinal uptake in diabetic patients on metformin: a matched case-control analysis","volume":"36","author":"Bybel","year":"2011","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.clml.2020.01.018_bib39","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.2006.08.2305","article-title":"Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma","volume":"25","author":"Juweid","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.01.018_bib40","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.3109\/10428194.2010.529208","article-title":"Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8\u20139 April 2010","volume":"51","author":"Meignan","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.01.018_bib41","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/hon.2563","article-title":"Prognostic role of baseline 18F-FDG PET\/CT parameters in MALT lymphoma","volume":"37","author":"Albano","year":"2019","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2020.01.018_bib42","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1158\/1078-0432.CCR-15-2825","article-title":"Molecular profile and FDG-PET\/CT total metabolic tumor volume improve risk classification at diagnosis for patients with diffuse large B-cell lymphoma","volume":"22","author":"Cottereau","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2020.01.018_bib43","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1007\/s00259-017-3907-x","article-title":"Combination of baseline FDG PET\/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma","volume":"45","author":"Toledano","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clml.2020.01.018_bib44","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00259-018-4173-2","article-title":"Prognostic role of baseline 18F-FDG PET\/CT metabolic parameters in Burkitt lymphoma","volume":"46","author":"Albano","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clml.2020.01.018_bib45","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1007\/s12149-018-1274-8","article-title":"Prognostic role of pretreatment 18F-FDG PET\/CT in primary brain lymphoma","volume":"32","author":"Albano","year":"2018","journal-title":"Ann Nucl Med"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020300653?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020300653?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:34:48Z","timestamp":1761870888000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265020300653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S2152265020300653"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2020.01.018","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"18F-FDG PET or PET\/CT in Mantle Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2020.01.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}